Four classes of non-statin medicine lower LDL cholesterol: ezetimibe, PCSK9 inhibitors, inclisiran and bempedoic acid. Three of them have large trials showing fewer major cardiovascular events. The fourth, inclisiran, lowers LDL strongly, but its outcome trial has not reported yet.
"Alternative" is only partly the right word. In most of the big trials these medicines were added to a statin, not swapped for one. This guide describes what each class does and what was shown, and in whom. It does not recommend any of them.
Key takeaways
- Ezetimibe, PCSK9 antibodies and bempedoic acid each reduced cardiovascular events in a large randomized trial.
- Most of that evidence comes from people at high risk, and most of them were also taking a statin.
- Bempedoic acid is the one class tested specifically in people who could not or would not take statins.
- Inclisiran roughly halves LDL cholesterol, and whether that prevents events is still being tested.
- Which medicine fits, if any, is a decision for you and your prescriber.
The four classes at a glance
| Class | How it lowers LDL | Outcome trial evidence |
|---|---|---|
| Ezetimibe (pill) | Reduces cholesterol absorption in the gut | Fewer events when added to a statin after a heart attack or unstable angina |
| PCSK9 antibodies: evolocumab, alirocumab (self-injection) | Block PCSK9, a protein that removes LDL receptors from the liver | Fewer events in people with artery disease or diabetes, on top of statins |
| Bempedoic acid (pill) | Slows cholesterol production in the liver by a different step than statins | Fewer events in people who were statin intolerant |
| Inclisiran (injection) | Switches off the liver's production of PCSK9 | Not yet proven; trial results expected in 2027 |
Ezetimibe
Ezetimibe is a pill that limits how much cholesterol the gut absorbs. Its main outcome trial, IMPROVE-IT, enrolled 18,144 people who had recently been hospitalized for a heart attack or unstable angina. Everyone took a statin, and half also took ezetimibe.
Adding ezetimibe brought average LDL cholesterol down from about 70 mg/dL to about 54 mg/dL. Over seven years, the main cardiovascular outcome occurred in 32.7% of the ezetimibe group and 34.7% of the statin-only group, an absolute difference of 2.0 percentage points.1 Rates of muscle, gallbladder and liver side effects and cancer were similar in both groups.
The gain was modest, and the trial studied people at very high risk.
PCSK9 antibodies and inclisiran
PCSK9 is a protein that breaks down the liver's LDL receptors. Antibodies that block it leave more receptors working, and more LDL is cleared from the blood. They are given by injection under the skin.
In the FOURIER trial, 27,564 people with established artery disease who were already on statins received evolocumab or placebo. LDL cholesterol fell by 59%, to a median of 30 mg/dL. Over about two years, the main outcome occurred in 9.8% of the evolocumab group and 11.3% of the placebo group.2 Injection-site reactions were the only side effect that was clearly more common.
A newer trial, VESALIUS-CV, tested the same medicine in 12,257 people with atherosclerosis or diabetes who had never had a heart attack or stroke. Over a median of 4.6 years, the five-year rate of coronary death, heart attack or ischemic stroke was 6.2% with evolocumab and 8.0% with placebo.3 Participants were at high risk, so this is not evidence for low-risk adults.
Inclisiran works on the same target as the antibodies, by a different route. It is a small interfering RNA that stops liver cells from making PCSK9. Its effect lasts for months, so it is given far less often than the antibodies.
In two phase 3 trials of people who had elevated LDL despite statin treatment, inclisiran reduced LDL cholesterol by about 50%.4
What is missing is proof that this LDL drop prevents heart attacks and strokes. The investigators of ORION-4, a trial of more than 16,000 people with existing cardiovascular disease, wrote in 2026 that inclisiran's efficacy and safety have not been proven in a cardiovascular outcomes trial and that results are expected in early 2027.5
See how low LDL should go for what these trials showed about very low LDL levels.
Bempedoic acid
Bempedoic acid is a pill that slows cholesterol production in the liver, at a different step than statins. It was linked to few muscle side effects in earlier studies, which is why it was tested in people who had trouble with statins.
The CLEAR Outcomes trial enrolled 13,970 people who were unable or unwilling to take statins because of side effects and who had, or were at high risk for, cardiovascular disease. Over a median of about 40 months, a major cardiovascular event occurred in 11.7% of the bempedoic acid group and 13.3% of the placebo group.6
There are limits. LDL fell by about 21 percentage points more than with placebo, a smaller drop than the strongest statins give. The medicine had no significant effect on death from cardiovascular causes or from any cause. Gout and gallstones were more common with it: gout in 3.1% versus 2.1%, gallstones in 2.2% versus 1.2%.
What these trials do and do not tell you
- Who was studied. Nearly all participants had established disease, diabetes or other high risk. Results may not carry over to people at low risk.
- What the comparison was. Most trials added the medicine to a statin. Only the bempedoic acid trial focused on people not taking statins.
- How big the benefit was. Absolute differences were between about 1.5 and 2 percentage points over the trial periods.
The 2026 ACC/AHA guideline gives non-statin medicines a larger role than earlier US guidance and supports combining them with a statin when a statin alone is not enough. Statins remain the foundation in that guideline.
Never start, stop or switch a cholesterol medication without speaking with your prescriber first. If you think a statin is causing symptoms, read statin side effects and take your notes to that appointment.
Next step: find out how far you are from your goal
Whether a second medicine is even a question depends on your LDL and ApoB on current treatment and on your overall risk. Both Cardio Res-Q assessments, the Comprehensive Assessment ($775) and the Enhanced Assessment ($999), measure ApoB and Lp(a) as part of the lab panel.
The Cardio Res-Q program page lists what each includes. If you are already treated, start with Already on a Statin?. The clinic prescribes statins and non-statin medicines case by case.
Are You a Candidate for Cardio Res-Q?
Three quick questions about the risk factors we screen for. Your answers stay between you and the clinic.
Frequently asked questions
Is there a cholesterol medicine that works as well as a statin?
It depends on what "works" means. PCSK9 antibodies and inclisiran lower LDL by about half or more, in the same range as the strongest statins. But statins have the longest and largest record of preventing heart attacks and strokes, and most trials of the newer medicines added them to a statin instead of replacing it.
What was tested in people who cannot take statins?
Bempedoic acid has the main trial in this group. In nearly 14,000 statin-intolerant people at high risk, it lowered major cardiovascular events from 13.3% to 11.7% over about 40 months. It did not significantly change the death rate, and gout and gallstones were more common.
Do these medicines lower Lp(a)?
None of them is approved to treat Lp(a). The first outcome trial of a drug designed to lower Lp(a) did not meet its main goal in 2026. A high Lp(a) is managed by controlling the other risk factors more firmly.
Related reading
This article is for general education and is not medical advice. Decisions about testing and medication should be made with your clinician. If you have chest pain or other symptoms of a heart attack, call 911.
